Bayer And Onyx Announce Pivotal Nexavar Kidney Cancer Study Published In NEJM

Tue, 16 Jan 2007 10:00 AM EST

... Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) has announced that the New England Journal of Medicine has published their pivotal Phase III trial demonstrating that Nexavar® (sorafenib) tablets doubled median progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), or kidney cancer. [click link for full article] ...